Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 26 entries
Sorted by: Best Match Show Resources per page
Risk factors for the development of cystic fibrosis related liver disease.

Hepatology (Baltimore, Md.)

Slieker MG, Deckers-Kocken JM, Uiterwaal CS, van der Ent CK, Houwen RH.
PMID: 12939606
Hepatology. 2003 Sep;38(3):775-6; author reply 776-7. doi: 10.1053/jhep.2003.50403.

No abstract available.

Cite
Slieker MG, Deckers-Kocken JM, Uiterwaal CS, et al. Risk factors for the development of cystic fibrosis related liver disease. Hepatology. 2003;38(3):775-6; author reply 776-7doi: 10.1053/jhep.2003.50403.
Slieker, M. G., Deckers-Kocken, J. M., Uiterwaal, C. S., van der Ent, C. K., & Houwen, R. H. (2003). Risk factors for the development of cystic fibrosis related liver disease. Hepatology (Baltimore, Md.), 38(3), 775-6; author reply 776-7. https://doi.org/10.1053/jhep.2003.50403
Slieker, Martijn G, et al. "Risk factors for the development of cystic fibrosis related liver disease." Hepatology (Baltimore, Md.) vol. 38,3 (2003): 775-6; author reply 776-7. doi: https://doi.org/10.1053/jhep.2003.50403
Slieker MG, Deckers-Kocken JM, Uiterwaal CS, van der Ent CK, Houwen RH. Risk factors for the development of cystic fibrosis related liver disease. Hepatology. 2003 Sep;38(3):775-6; author reply 776-7. doi: 10.1053/jhep.2003.50403. PMID: 12939606.
Copy Download .nbib Format: NLM
Drug-induced hepatic injury.

Annals of internal medicine

POPPER H, SCHAFFNER F.
PMID: 14434187
Ann Intern Med. 1959 Dec;51:1230-52. doi: 10.7326/0003-4819-51-6-1230.

No abstract available.

Cite
POPPER H, SCHAFFNER F. Drug-induced hepatic injury. Ann Intern Med. 1959;51:1230-52doi: 10.7326/0003-4819-51-6-1230.
POPPER, H., & SCHAFFNER, F. (1959). Drug-induced hepatic injury. Annals of internal medicine, 511230-52. https://doi.org/10.7326/0003-4819-51-6-1230
POPPER, H, and SCHAFFNER, F. "Drug-induced hepatic injury." Annals of internal medicine vol. 51 (1959): 1230-52. doi: https://doi.org/10.7326/0003-4819-51-6-1230
POPPER H, SCHAFFNER F. Drug-induced hepatic injury. Ann Intern Med. 1959 Dec;51:1230-52. doi: 10.7326/0003-4819-51-6-1230. PMID: 14434187.
Copy Download .nbib Format: NLM
DRUGS and liver disease.

British medical journal

[No authors listed]
PMID: 13584882
Br Med J. 1958 Nov 08;2(5105):1149-50.

No abstract available.

Cite
DRUGS and liver disease. Br Med J. 1958;2(5105):1149-50
(1958). DRUGS and liver disease. British medical journal, 2(5105), 1149-50.
"DRUGS and liver disease." British medical journal vol. 2,5105 (1958): 1149-50.
DRUGS and liver disease. Br Med J. 1958 Nov 08;2(5105):1149-50. PMID: 13584882; PMCID: PMC2026735.
Copy Download .nbib Format: NLM
[So-called hepatic diabetes].

Casopis lekaru ceskych

OPPLT J, SYLLABA J.
PMID: 13396727
Cas Lek Cesk. 1956 Nov 09;95(44):1247-51.

No abstract available.

Cite
OPPLT J, SYLLABA J. O T. zv jaterním diabetu. [So-called hepatic diabetes]. Cas Lek Cesk. 1956;95(44):1247-51
OPPLT, J., & SYLLABA, J. (1956). O T. zv jaterním diabetu. [So-called hepatic diabetes]. Casopis lekaru ceskych, 95(44), 1247-51.
OPPLT, J, and SYLLABA, J. "O T. zv jaterním diabetu." [So-called hepatic diabetes]. Casopis lekaru ceskych vol. 95,44 (1956): 1247-51.
OPPLT J, SYLLABA J. O T. zv jaterním diabetu. [So-called hepatic diabetes]. Cas Lek Cesk. 1956 Nov 09;95(44):1247-51. Czech. PMID: 13396727.
Copy Download .nbib Format: NLM
The binge drinker's liver.

Medical times

HOLCOMBE R.
PMID: 13440327
Med Times. 1957 Jul;85(7):769-73.

No abstract available.

Cite
HOLCOMBE R. The binge drinker's liver. Med Times. 1957;85(7):769-73
HOLCOMBE, R. (1957). The binge drinker's liver. Medical times, 85(7), 769-73.
HOLCOMBE, R. "The binge drinker's liver." Medical times vol. 85,7 (1957): 769-73.
HOLCOMBE R. The binge drinker's liver. Med Times. 1957 Jul;85(7):769-73. PMID: 13440327.
Copy Download .nbib Format: NLM
Chronic liver disease. The scope of causes and treatments.

Postgraduate medicine

Babb RR.
PMID: 1589371
Postgrad Med. 1992 May 15;91(7):89-96. doi: 10.1080/00325481.1992.11701346.

Evaluation of chronic liver disease begins with a carefully taken history, thorough physical examination, and standard laboratory tests. Often, however, other studies are required, such as a viral hepatitis panel, serologic tests for autoimmune markers, tests for antimitochondrial antibodies,...

Cite
Babb RR. Chronic liver disease. The scope of causes and treatments. Postgrad Med. 1992;91(7):89-96doi: 10.1080/00325481.1992.11701346.
Babb, R. R. (1992). Chronic liver disease. The scope of causes and treatments. Postgraduate medicine, 91(7), 89-96. https://doi.org/10.1080/00325481.1992.11701346
Babb, R R. "Chronic liver disease. The scope of causes and treatments." Postgraduate medicine vol. 91,7 (1992): 89-96. doi: https://doi.org/10.1080/00325481.1992.11701346
Babb RR. Chronic liver disease. The scope of causes and treatments. Postgrad Med. 1992 May 15;91(7):89-96. doi: 10.1080/00325481.1992.11701346. PMID: 1589371.
Copy Download .nbib Format: NLM
[Clinical course and treatment of different forms of liver insufficiency].

Voenno-meditsinskii zhurnal

Khazanov AI, Aleksanov NS, Sycheva IK.
PMID: 5999457
Voen Med Zh. 1966 Jul;7:40-3.

No abstract available.

Cite
Khazanov AI, Aleksanov NS, Sycheva IK. Klinika i lechenie razlichnykh vidov pechenochnoĭ nedostatochnosti. [Clinical course and treatment of different forms of liver insufficiency]. Voen Med Zh. 1966;7:40-3
Khazanov, A. I., Aleksanov, N. S., & Sycheva, I. K. (1966). Klinika i lechenie razlichnykh vidov pechenochnoĭ nedostatochnosti. [Clinical course and treatment of different forms of liver insufficiency]. Voenno-meditsinskii zhurnal, 740-3.
Khazanov, A I, et al. "Klinika i lechenie razlichnykh vidov pechenochnoĭ nedostatochnosti." [Clinical course and treatment of different forms of liver insufficiency]. Voenno-meditsinskii zhurnal vol. 7 (1966): 40-3.
Khazanov AI, Aleksanov NS, Sycheva IK. Klinika i lechenie razlichnykh vidov pechenochnoĭ nedostatochnosti. [Clinical course and treatment of different forms of liver insufficiency]. Voen Med Zh. 1966 Jul;7:40-3. Russian. PMID: 5999457.
Copy Download .nbib Format: NLM
[The liver in congestive heart failure].

Ryoikibetsu shokogun shirizu

Yanagisawa N, Sugaya H, Terano A.
PMID: 8581633
Ryoikibetsu Shokogun Shirizu. 1995;(8):294-6.

No abstract available.

Cite
Yanagisawa N, Sugaya H, Terano A. [The liver in congestive heart failure]. Ryoikibetsu Shokogun Shirizu. 1995;(8):294-6
Yanagisawa, N., Sugaya, H., & Terano, A. (1995). [The liver in congestive heart failure]. Ryoikibetsu shokogun shirizu, (8), 294-6.
Yanagisawa, N, et al. "[The liver in congestive heart failure]." Ryoikibetsu shokogun shirizu vol. ,8 (1995): 294-6.
Yanagisawa N, Sugaya H, Terano A. [The liver in congestive heart failure]. Ryoikibetsu Shokogun Shirizu. 1995;(8):294-6. Japanese. PMID: 8581633.
Copy Download .nbib Format: NLM
Calling a stage-based treatment model for chronic liver diseases in China mainland.

Annals of hepatology

Liu X, Xu J.
PMID: 31711913
Ann Hepatol. 2020 Nov - Dec;19(6):585-589. doi: 10.1016/j.aohep.2019.09.007. Epub 2019 Oct 23.

China is regarded as the "leader in liver diseases" because that one-fifth of the population was affected by some forms of liver diseases in this developing country. In addition to common infectious liver diseases (such as viral hepatitis and...

Cite
Liu X, Xu J. Calling a stage-based treatment model for chronic liver diseases in China mainland. Ann Hepatol. 2019;19(6):585-589doi: 10.1016/j.aohep.2019.09.007.
Liu, X., & Xu, J. (2020). Calling a stage-based treatment model for chronic liver diseases in China mainland. Annals of hepatology, 19(6), 585-589. https://doi.org/10.1016/j.aohep.2019.09.007
Liu, Xueqin, and Xu, Jian. "Calling a stage-based treatment model for chronic liver diseases in China mainland." Annals of hepatology vol. 19,6 (2020): 585-589. doi: https://doi.org/10.1016/j.aohep.2019.09.007
Liu X, Xu J. Calling a stage-based treatment model for chronic liver diseases in China mainland. Ann Hepatol. 2020 Nov - Dec;19(6):585-589. doi: 10.1016/j.aohep.2019.09.007. Epub 2019 Oct 23. PMID: 31711913.
Copy Download .nbib Format: NLM
Chronic liver disease: scavenger hunt for novel therapies.

Lancet (London, England)

Patten DA, Shetty S.
PMID: 29353605
Lancet. 2018 Jan 13;391(10116):104-105. doi: 10.1016/S0140-6736(17)32671-5.

No abstract available.

Cite
Patten DA, Shetty S. Chronic liver disease: scavenger hunt for novel therapies. Lancet. 2018;391(10116):104-105doi: 10.1016/S0140-6736(17)32671-5.
Patten, D. A., & Shetty, S. (2018). Chronic liver disease: scavenger hunt for novel therapies. Lancet (London, England), 391(10116), 104-105. https://doi.org/10.1016/S0140-6736(17)32671-5
Patten, Daniel A, and Shetty, Shishir. "Chronic liver disease: scavenger hunt for novel therapies." Lancet (London, England) vol. 391,10116 (2018): 104-105. doi: https://doi.org/10.1016/S0140-6736(17)32671-5
Patten DA, Shetty S. Chronic liver disease: scavenger hunt for novel therapies. Lancet. 2018 Jan 13;391(10116):104-105. doi: 10.1016/S0140-6736(17)32671-5. PMID: 29353605.
Copy Download .nbib Format: NLM
[Cystic fibrosis associated with liver disease].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie

Debray D.
PMID: 22682485
Arch Pediatr. 2012 May;19:S23-6. doi: 10.1016/S0929-693X(12)71104-1.

In cystic fibrosis (CF), approximately 5-10% of the patients develop multilobular cirrhosis during the first decade of life. Most of these will develop signs of portal hypertension with complications, mainly variceal bleeding during the second decade, while liver failure...

Cite
Debray D. L'atteinte hépatique de la mucoviscidose. [Cystic fibrosis associated with liver disease]. Arch Pediatr. 2012;19:S23-6doi: 10.1016/S0929-693X(12)71104-1.
Debray, D. (2012). L'atteinte hépatique de la mucoviscidose. [Cystic fibrosis associated with liver disease]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 19S23-6. https://doi.org/10.1016/S0929-693X(12)71104-1
Debray, D. "L'atteinte hépatique de la mucoviscidose." [Cystic fibrosis associated with liver disease]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie vol. 19 (2012): S23-6. doi: https://doi.org/10.1016/S0929-693X(12)71104-1
Debray D. L'atteinte hépatique de la mucoviscidose. [Cystic fibrosis associated with liver disease]. Arch Pediatr. 2012 May;19:S23-6. doi: 10.1016/S0929-693X(12)71104-1. French. PMID: 22682485.
Copy Download .nbib Format: NLM
Hepatology 2014: where are we going?.

Minerva gastroenterologica e dietologica

Pellicano R, El-Serag HB.
PMID: 24632763
Minerva Gastroenterol Dietol. 2014 Mar;60(1):1-4.

No abstract available.

Cite
Pellicano R, El-Serag HB. Hepatology 2014: where are we going?. Minerva Gastroenterol Dietol. 2014;60(1):1-4
Pellicano, R., & El-Serag, H. B. (2014). Hepatology 2014: where are we going?. Minerva gastroenterologica e dietologica, 60(1), 1-4.
Pellicano, R, and El-Serag, H B. "Hepatology 2014: where are we going?." Minerva gastroenterologica e dietologica vol. 60,1 (2014): 1-4.
Pellicano R, El-Serag HB. Hepatology 2014: where are we going?. Minerva Gastroenterol Dietol. 2014 Mar;60(1):1-4. PMID: 24632763.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 26 entries